Pink Sheet

@PharmaPinkSheet

Pink Sheet delivers analysis & commentary focused on regulatory implications, including high value perspectives from insiders & thought leaders across the globe

Global
Vrijeme pridruživanja: prosinac 2012.

Tweetovi

Blokirali ste korisnika/cu @PharmaPinkSheet

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @PharmaPinkSheet

  1. prije 11 sati

    New CLL Treatment Paradigm Nears In EU For AbbVie

    Poništi
  2. prije 12 sati

    EU Firms Called In As Coronavirus Cases Soar

    Poništi
  3. prije 16 sati

    US FDA Finds Negligible Cancer Risks In Metformin Products

    Poništi
  4. prije 19 sati

    European CHMP Opinions and MAA Updates

    Poništi
  5. prije 20 sati

    PDUFA VII: Will Gene Therapy's Rise Influence Talks?

    Poništi
  6. prije 21 sat

    GDUFA III: How Much Of A Fee Increase Can Industry Stomach?

    Poništi
  7. prije 22 sata

    Predicting The User Fee Reauthorization Schedule

    Poništi
  8. prije 23 sata

    BsUFA III: Could Regulatory Science Research Emerge With Other Tweaks?

    Poništi
  9. 4. velj

    US Embassy Slams Dutch Compounding Policy

    Poništi
  10. 4. velj

    Drug Shortage Crisis Worsens

    Poništi
  11. 4. velj

    FDA, FTC Join Forces To Eliminate Barriers To Biosimilar Competition

    Poništi
  12. 4. velj

    Biosimilar Information Wars: Draft Guidance Seeks To Clamp Down On Efforts To Hinder Uptake In The US

    Poništi
  13. 4. velj

    Fast-Track Fail For Kite’s KTE-X19 EU Review?

    Poništi
  14. 4. velj

    AstraZeneca’s Roxadustat And The Challenge Of Shifting Medicare Coverage Policy

    Poništi
  15. 3. velj

    Novel Virus Brings Novel Threats To Global Pharmaceutical Manufacturing

    Poništi
  16. 3. velj

    Belgian Law Seeks To Tackle Drug Shortages

    Poništi
  17. 3. velj

    Visible Particles, Drug Shortages, DSCSA Spotlighted In CDER’s 2020 Quality/GMP Guidance Agenda

    Poništi
  18. 3. velj

    Novo’s Rybelsus Pill Set To Disrupt Europe’s Diabetes Market

    Poništi
  19. 3. velj

    Decentralized Clinical Trials Among Topics Slated For CDER Guidance In 2020

    Poništi
  20. 1. velj

    Keeping Track: Aimmune’s Peanut Allergen Approved; Novartis’ Inclisiran, Pfizer/Lilly’s Tanezumab, Bayer’s Nifurtimox Submitted

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·